However, as has been raised previously, there are concerns with the 80% CI (Vs Enhertu's registrational approval of 95% CI) and the patient randomisation in the HER-VAXX trial. Best case scenario is a third party acquiring the B Cell platform and rerunning this trial. However, pretty risky to expect a more favourable outcome and only 12 years of patent life from today.
IMU Price at posting:
3.8¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)